VFA
ATRA icon

Virtus Fund Advisers’s Atara Biotherapeutics ATRA Stock Holding History

Virtus Fund Advisers’s Portfolio ATRA Stock Details ATRA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q4 		$434K Buy
+958
New +$354K ﹤0.01% 337

Other funds holding ATRA

BG
Baupost Group Boston, Massachusetts $5.42B AUM 22.93% 1-Year Est. Return
ACH
ArrowMark Colorado Holdings Denver, Colorado $2.4B AUM 42.85% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return
BM
Bridger Management New York $150M AUM 17.71% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
EAM
Eagle Asset Management St Petersburg, Florida $19.6B AUM 41.58% 1-Year Est. Return
CTA
Carillon Tower Advisers St. Petersburg, Florida $16.4B AUM 64.75% 1-Year Est. Return
Neuberger Berman Group
Neuberger Berman Group New York $150B AUM 40.08% 1-Year Est. Return

Virtus Fund Advisers's ATRA Position: Q4 2017 in Review

Virtus Fund Advisers opened a new position in Atara Biotherapeutics (ATRA) in Q4 2017: 958 shares worth $434K. The stake represents ﹤0.01% of the portfolio and ranks #337 among its holdings.

86 funds tracked by Wall St. Rank hold ATRA as of Q4 2017.

  • Virtus Fund Advisers held 958 shares of Atara Biotherapeutics worth $434K as of Q4 2017.
  • Atara Biotherapeutics was a new Virtus Fund Advisers position in Q4 2017.
  • Atara Biotherapeutics made up ﹤0.01% of Virtus Fund Advisers's portfolio in Q4 2017, its #337 holding.
  • 86 funds tracked by Wall St. Rank held Atara Biotherapeutics as of Q4 2017.

Based on Virtus Fund Advisers's 13F filing for Q4 2017, filed 9 Feb 2018.